CoChat

Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies

Open access

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

Abstract

models by enabling precise control over various parameters. These parameters include the properties of the extracellular matrix, mechanical forces exerted on cells, the physico-chemical environment, cell composition, and the architecture of the tumor microenvironment. Such fine control allows ToC to closely replicate the complex microenvironment and interactions within tumors, facilitating the study of cancer progression and therapeutic responses in a highly representative manner. Importantly, by incorporating patient-derived cells or tumor xenografts, ToC models have demonstrated promising results in terms of clinical validation. We also examined the potential of ToC for pharmaceutical industries in which ToC adoption is expected to occur gradually. Looking ahead, given the high failure rate of clinical trials and the increasing emphasis on the 3Rs principles (replacement, reduction, refinement of animal experimentation), ToC models hold immense potential for cancer research. In the next decade, data generated from ToC models could potentially be employed for discovering new therapeutic targets, contributing to regulatory purposes, refining preclinical drug testing and reducing reliance on animal models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d3lc00531c

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pie chart illustrating the proportion of the different extracellular matrix types used in ToC: collagen 49%, Matrigel 23%, fibrin 8%, gelatin 6%, hybrid natural 6%, agarose 4%, hybrid synthetic 3%. (Right panel) Hybrid natural: hydrogels can be created by interpenetrating growth-factorreduced Matrigel matrix with MMP-degradable ha hydrogel for brain tissue-mimicking extracellular matrix. RGD peptides are conjugated onto acrylated hyaluronic acid (HA -AC) and crosslinked with MMP-degradable crosslinker. 27
Fig. 1 Pie chart illustrating the proportion of the different extracellular matrix types used in ToC: collagen 49%, Matrigel 23%, fibrin 8%, gelatin 6%, hybrid natural 6%, agarose 4%, hybrid synthetic 3%. (Right panel) Hybrid natural: hydrogels can be created by interpenetrating growth-factorreduced Matrigel matrix with MMP-degradable ha hydrogel for brain tissue-mimicking extracellular matrix. RGD peptides are conjugated onto acrylated hyaluronic acid (HA -AC) and crosslinked with MMP-degradable crosslinker. 27CC-BY · From the PDF
Fig. 2 Pie chart illustrating the proportion of different oxygen control strategies used in ToC: cell consumption 30%, gas channel 30%, chemical induction 22%, hypoxic incubator 15%, other 4%. (Top panel) Other: the dissolved oxygen level can be regulated by modulating pneumatic valves opening. This method simultaneously changes the gas composition and the pressure-driven flow. 62 (Bottom panel) Gas channel: to control dissolved oxygen levels in the media and gel channels, gas mixtures can be supplied to the two separated gas channels. To prevent from atmospheric oxygen diffusion, a polycarbonate film is embedded on top of the gas channels. 58
Fig. 2 Pie chart illustrating the proportion of different oxygen control strategies used in ToC: cell consumption 30%, gas channel 30%, chemical induction 22%, hypoxic incubator 15%, other 4%. (Top panel) Other: the dissolved oxygen level can be regulated by modulating pneumatic valves opening. This method simultaneously changes the gas composition and the pressure-driven flow. 62 (Bottom panel) Gas channel: to control dissolved oxygen levels in the media and gel channels, gas mixtures can be supplied to the two separated gas channels. To prevent from atmospheric oxygen diffusion, a polycarbonate film is embedded on top of the gas channels. 58CC-BY · From the PDF
Fig. 3 Pie chart illustrating the proportion of different cell sources used for ToC: cell line 69%, primary cells (HUVECs, PBMCs, primary fibroblasts) 28%, PDX 3%, from fresh tumor to chip (freshly resected tumor, CTCs), IPS cells 1%, organoids 2%. (Left panel) Tumors are harvested from PDXs. After dissociation and filtration isolation, spheroids are produced in ultra-low attachment plate and seeded in the toc. 85 (Right panel) Freshly resected primary tumors can be subjected to tumor digestion using a human primary tumor dissociation kit and then seeded in a micro-well array ToC. 89
Fig. 3 Pie chart illustrating the proportion of different cell sources used for ToC: cell line 69%, primary cells (HUVECs, PBMCs, primary fibroblasts) 28%, PDX 3%, from fresh tumor to chip (freshly resected tumor, CTCs), IPS cells 1%, organoids 2%. (Left panel) Tumors are harvested from PDXs. After dissociation and filtration isolation, spheroids are produced in ultra-low attachment plate and seeded in the toc. 85 (Right panel) Freshly resected primary tumors can be subjected to tumor digestion using a human primary tumor dissociation kit and then seeded in a micro-well array ToC. 89CC-BY · From the PDF
Fig. 4 Pie chart illustrating the proportion of different toc designs used to mimic cell architecture: compartmentalized chip 39%, micro-wells array 18%, 2D chip 16%, membrane chip 11%, lumen chip 8%, other 8%. (Top left panel) The glioblastoma toc model is a compartmentalized chip with three concentric cell culture regions separated by pillars: namely, the vasculature, stroma, and tumor regions surrounded by media channels. 109 (Top right) In this micro-well array ToC, cancer and stromal cells are encapsulated in Matrigel and seeded into the bottom layer, while flow is applied in the top layer. 116 (Bottom left panel) The 2-channel membrane toc contains human lung epithelial cells and a low density of lung cancer cells cultured on the upper surface of a porous ECM-coated membrane. Human lung microvascular endothelial cells are cultured on all four walls of the lower channel, forming a hollow vascular lumen. 71 (Bottom right panel) The lumen ToC is composed of two cylindrical channels embedded within a 3D collagen matrix. One channel is covered with endothelial cells to form a perfusable biomimetic blood vessel, and the other channel is covered with pancreatic cancer cells to form a pancreatic cancer duct. 129
Fig. 4 Pie chart illustrating the proportion of different toc designs used to mimic cell architecture: compartmentalized chip 39%, micro-wells array 18%, 2D chip 16%, membrane chip 11%, lumen chip 8%, other 8%. (Top left panel) The glioblastoma toc model is a compartmentalized chip with three concentric cell culture regions separated by pillars: namely, the vasculature, stroma, and tumor regions surrounded by media channels. 109 (Top right) In this micro-well array ToC, cancer and stromal cells are encapsulated in Matrigel and seeded into the bottom layer, while flow is applied in the top layer. 116 (Bottom left panel) The 2-channel membrane toc contains human lung epithelial cells and a low density of lung cancer cells cultured on the upper surface of a porous ECM-coated membrane. Human lung microvascular endothelial cells are cultured on all four walls of the lower channel, forming a hollow vascular lumen. 71 (Bottom right panel) The lumen ToC is composed of two cylindrical channels embedded within a 3D collagen matrix. One channel is covered with endothelial cells to form a perfusable biomimetic blood vessel, and the other channel is covered with pancreatic cancer cells to form a pancreatic cancer duct. 129CC-BY · From the PDF
Fig. 5 Pie chart illustrating the proportion of different vascularization methods used in ToC: self-assembly 42%, sacrificial mold 41%, patterned microchannel 17%. (Left panel) Lumen can be formed by removing a retaining rod from collagen and further cellularizing with endothelial cells. 128 (Right panel) Endothelial cells elongate, form vacuoles and subsequently self-assemble into interconnected perfusable vascular networks. 137
Fig. 5 Pie chart illustrating the proportion of different vascularization methods used in ToC: self-assembly 42%, sacrificial mold 41%, patterned microchannel 17%. (Left panel) Lumen can be formed by removing a retaining rod from collagen and further cellularizing with endothelial cells. 128 (Right panel) Endothelial cells elongate, form vacuoles and subsequently self-assemble into interconnected perfusable vascular networks. 137CC-BY · From the PDF
Fig. 6 Pie chart illustrating the proportion of different information extracted from ToC: drug-induced death 52%, proteomic 23%, transcriptomic 14%, secretome 8%, metabolism 2%. (Right panel) Drug-induced death: open-source computational method can be used to extract the temporal kinetics and the spatial maps of cancer death. 150
Fig. 6 Pie chart illustrating the proportion of different information extracted from ToC: drug-induced death 52%, proteomic 23%, transcriptomic 14%, secretome 8%, metabolism 2%. (Right panel) Drug-induced death: open-source computational method can be used to extract the temporal kinetics and the spatial maps of cancer death. 150CC-BY · From the PDF
Fig. 7 Pie chart illustrating the proportion of different treatments tested in ToC: chemotherapy 63%, targeted therapy 23%, immunotherapy 7%, other 6%, radiotherapy 1% (right panel) concentration gradient generator to test different drug combinations. 80 (Left panel) Diffusion of antibody inside MCF7 spheroid. 124
Fig. 7 Pie chart illustrating the proportion of different treatments tested in ToC: chemotherapy 63%, targeted therapy 23%, immunotherapy 7%, other 6%, radiotherapy 1% (right panel) concentration gradient generator to test different drug combinations. 80 (Left panel) Diffusion of antibody inside MCF7 spheroid. 124CC-BY · From the PDF
Fig. 8 Heatmap representing the number of publications according to the cellular complexity (mono-culture, bi-culture, tri-culture) with different cell sources (cell line, primary cells or fresh tumor) for different drug treatments (chemotherapy, immunotherapy, targeted therapy) and information extracted (drug-induced death, transcriptomic, proteomic).
Fig. 8 Heatmap representing the number of publications according to the cellular complexity (mono-culture, bi-culture, tri-culture) with different cell sources (cell line, primary cells or fresh tumor) for different drug treatments (chemotherapy, immunotherapy, targeted therapy) and information extracted (drug-induced death, transcriptomic, proteomic).CC-BY · From the PDF
Fig. 9 Evolution of cellular complexity and drug tested over time during the last 15 years of ToC development. Histograms illustrating evolution of A. cell complexity, B. cell source and C. tested therapy in publications.
Fig. 9 Evolution of cellular complexity and drug tested over time during the last 15 years of ToC development. Histograms illustrating evolution of A. cell complexity, B. cell source and C. tested therapy in publications.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–222 of 222

Research works printed but not linked: 6

  1. T. C. Chang, A. M. Mikheev, W. Huynh, R. J. Monnat, R. C. Rostomily and A. Folch, Parallel Microfluidic Chemosensitivity Testing on Individual Slice Cultures, Lab Chip, 2014, 14(23), 4540-4551, DOI: 10.1039/b000000x/NIH. · doi:10.1039/b000000x/nih
  2. W. Han, S. Chen and W. Yuan, et al., Oriented collagen fibers direct tumor cell intravasation, Proc. Natl. Acad. Sci.
  3. M. Glicksman, Z. Li and S. Markossian, et al., In Vitro Cell Based Assays, Assay Guidance Manual, 2023. 149
  4. M. S. Manak, J. S. Varsanik and B. J. Hogan, et al., Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning, Nat. Biomed. Eng., 2018, 47(3), 549-562, DOI: 10.1038/s41551- 018-0285-z.Live-cell. 154 · doi:10.1038/s41551-018-0285-z.live-cell
  5. K. Sherkar, S. Choudante and O. Sumant, Organ-Tumor-on- a-Chip Market by Type (Lung Tumor-on-a-Chip, Bone Marrow Tumor-on-a-Chip, Brain Tumor-on-a-Chip, Breast Tumor-on-a- Chip, Urinary System Tumor-on-a-Chip, Intestine Tumor-on-a- Chip, and Liver Tumor-on-a-Chip): Global Opportunity Analysis and Industry Forecast, 2021-2030, 2021.
  6. D. Venturoli and B. Rippe, Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability, Am. J. Physiol. -Ren. Physiol., 2005, 288, 605-613, DOI: 10.1152/ajprenal.00171.2004.-Polydisperse. 225 · doi:10.1152/ajprenal.00171.2004.-polydisperse

Cited by

See all 59

Metadata

Authors
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., Wilhelm, C., Zalcman, G., Parrini, M. C., & Descroix, S.
Affiliations
  • Inserm (FR)
  • Institut Pierre-Gilles de Gennes pour la Microfluidique (FR)
  • Pfizer (United States) (US)
  • Macromolécules et Microsystèmes en Biologie et Médecine, UMR 168, Institut Curie, Institut Pierre Gilles de Gennes, 6 rue Jean Calvin, 75005, Paris, France
  • Genentech (US)
  • Institut Curie (FR)
  • Stress and Cancer Laboratory, Inserm, U830, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France
Corresponding author
Descroix, Stéphanie
Venue
Lab on a Chip
Published
2023
Volume
23
Issue
18
Pages
3906-3935
ISSN
  • 1473-0189 (ISSN-L)
  • 1473-0197
OpenAlex
W4385969151
Cited by
58
References
222
Citations by year
2026: 18 · 2025: 24 · 2024: 15 · 2023: 1
FWCI
1.30
Type
journal article
Language
en
Open access
Locations
  • Lab on a Chip (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
Funders
  • Centre National de la Recherche Scientifique
  • Association Nationale de la Recherche et de la Technologie
  • Institut Pierre-Gilles de Gennes (ANR-10-IDEX-0001-02 PSL, ANR-10-EQPX-34, ANR-10-LABX-31)
  • Fondation ARC pour la Recherche sur le Cancer (PGA12021010002992_3578)
  • Institut National de la Santé et de la Recherche Médicale (19CR046-01, 53712INSERM/ITMO 20-DESCROIX 04/24)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
Keywords
tumor-on-a-chip, 3D tumor models, tumor microenvironment, patient-derived cells, tumor xenografts, clinical validation, preclinical drug testing, 3Rs, tumor progression, treatment response, extracellular matrix, mechanobiology, pharmaceutical industry
MeSH terms
Animals, Drug Industry, Extracellular Matrix, Humans, Neoplasms, Cell Culture Techniques, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.